Skip to main content
. 2024 May 10;131(1):23–36. doi: 10.1038/s41416-024-02698-4

Fig. 6. EMT in tumor cells is a predictive biomarker for a poor clinical outcome after ICI therapy in patients with PD-L1-high NSCLC (IHC cohort).

Fig. 6

Tumor tissues from 90 patients with NSCLC who underwent ICI therapy were subjected to IHC. The patients were divided into PD-L1-low and PD-L1-high groups using a cutoff of a PD-L1 TPS of 1 as well as EMT molecule-low and EMT molecule-high groups using a cutoff of the H-score determined from the Euclidean distance on the receiver operating characteristic curve. a Representative IHC staining images of Slug, Twist1, vimentin, and E-cadherin in patients with PD-L1-low and PD-L1-high NSCLC. b Correlations between the H-scores of PD-L1 and EMT molecules in all patients, patients showing a complete response (CR) and partial response (PR), patients showing stable disease (SD), and patients showing progressive disease (PD). c Correlations between the H-score of EMT molecules and the numbers of CD8+, CD163+, and FOXP3+ cells in patients showing CR plus PR and PD, respectively, in PD-L1-high NSCLCs. d Kaplan−Meier analysis of overall survival and PFS after ICI therapy according to PD-L1 expression and the combined status of PD-L1 expression and EMT molecule expression. The survival difference was analyzed using the log-rank test. Correlations among variables were calculated using Spearman’s correlation test.